A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: ALK Tang
- Phone Number: +8618502921630
- Email: xftang@allinkbio.com
Study Locations
-
-
-
Macquarie, Australia
- Recruiting
- Macquarie University Hospital
-
Contact:
- Dr Andrew Parsonson
-
-
New South Wales
-
Wollongong, New South Wales, Australia, 2500
- Recruiting
- Cancer Care Wollongong
-
Contact:
- Dr. Udit Nindra
-
-
Queensland
-
Birtinya, Queensland, Australia
- Recruiting
- Sunshine Coast University Private Hospital
-
Contact:
- Dr Michelle Morris
-
South Brisbane, Queensland, Australia
- Recruiting
- Mater Cancer Care Center
-
Contact:
- Dr Catherine Shannon
-
-
-
-
-
Chongqing, China
- Recruiting
- Chongqing University Cancer Hospital
-
Contact:
- Yongsheng Li
-
-
Anhui
-
Hefei, Anhui, China
- Recruiting
- AnHui Provincial Cancer Hospital
-
Contact:
- Yifu He
-
-
Fujian
-
Fuzhou, Fujian, China
- Recruiting
- Fujian Cancer Hospital
-
Contact:
- Jianwei Yang
-
Fuzhou, Fujian, China
- Recruiting
- Fujian Medical University Union Hospital
-
Contact:
- Xiaoyan Lin
-
Xiamen, Fujian, China
- Recruiting
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Linli Chen
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Ruihua Xu
-
Guangzhou, Guangdong, China
- Recruiting
- Guangdong Province People's Hospital
-
Contact:
- Jian Xiao
-
Shantou, Guangdong, China
- Recruiting
- Cancer Hospital of Shantou University Medical College
-
Contact:
- Yi Jiang
-
-
Guangxi
-
Nanning, Guangxi, China
- Recruiting
- Guangxi Medical University Cancer Hospital
-
Contact:
- Yongqiang Li
-
-
Hebei
-
Chengde, Hebei, China
- Recruiting
- Affiliated Hospital of Chengde Medical University
-
Contact:
- Qingshan Li
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Recruiting
- Harbin Medical University Canser Hospital
-
Contact:
- Yanqiao Zhang
-
-
Henan
-
Luoyang, Henan, China
- Recruiting
- The First Affiliated Hospital of Henan University of Science & Technology
-
Contact:
- Shegan Gao, Ruinuo Jia
-
Zhengzhou, Henan, China
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Suxia Luo, Yanqiu Zhao
-
-
Hubei
-
Wuhan, Hubei, China
- Recruiting
- Tongji Hospital, Tongji Medical College of HUST
-
Contact:
- Xianglin Yuan
-
Wuhan, Hubei, China
- Recruiting
- Hubei Cancer Hospital
-
Contact:
- Xinjun Liang
-
Wuhan, Hubei, China
- Recruiting
- Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
-
Contact:
- Rui Meng
-
-
Hunan
-
Changsha, Hunan, China
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Zhenyang Liu
-
Yongzhou, Hunan, China
- Recruiting
- The Central Hospital of Yongzhou
-
Contact:
- Sijuan Ding
-
-
Jiangsu
-
Changzhou, Jiangsu, China
- Recruiting
- The First People's Hospital of Changzhou
-
Contact:
- Jun Wu
-
Nanjing, Jiangsu, China
- Recruiting
- Jiangsu Province Hospital
-
Contact:
- Yongmei Yin
-
Suzhou, Jiangsu, China
- Recruiting
- The Second Affiliated Hospital of Soochow University
-
Contact:
- Zhixiang Zhuang
-
Xuzhou, Jiangsu, China
- Recruiting
- Xuzhou Central Hospital ( Southeast University Affiliated Hopstal )
-
Contact:
- Liang Han
-
-
Jiangxi
-
Ganzhou, Jiangxi, China
- Recruiting
- First Affiliated Hospital of Gannan Medical University
-
Contact:
- Huaqiu Shi
-
-
Liaoning
-
Shenyang, Liaoning, China
- Recruiting
- Liaoning Cancer Hospital
-
Contact:
- Jingdong Zhang
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Shandong Cancer Hospital
-
Contact:
- Qi Dang, Xiaoyong Tang
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Recruiting
- Shanghai East Hospital
-
Contact:
- Zhou fei
- Phone Number: 86-021-38804818
- Email: story185@126.com
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Yan Zhang
-
-
Yunnan
-
Kunming, Yunnan, China
- Recruiting
- Yunnan Cancer Hospital
-
Contact:
- Lin Xie
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- The First Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Haiping Jiang, Jian Liu
-
Hangzhou, Zhejiang, China
- Recruiting
- Sir Run Run Shaw Hospital Zhejiang University School of Medical
-
Contact:
- Yong Fang
-
-
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Denver Drug Development Unit
-
Contact:
- Dr.Jason Henry
-
-
Florida
-
Orlando, Florida, United States, 32827
- Recruiting
- UCF Lake Nona Cancer Center
-
Contact:
- Dr.Cesar Perez
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- University Medical Center New Orleans
-
Contact:
- Dr. Shou-Ching Tang
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute Oncology Partners
-
Contact:
- Dr. Meredith Pelster
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women ≥18 and ≤75 years old on the day of signing the ICF
- At least 1 measurable lesion per RECIST v1.1
- Expected survival ≥3 months
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1
- Adequate organ function
- Female participants of childbearing potential or male participants whose partner is a female of childbearing potential agree to use medically effective contraceptive methods from the date of signing the ICF until at least 6 months after the last dose of the IP, and during this period, male participants are not allowed to donate sperms
Exclusion Criteria:
- Active or pre-existing autoimmune diseases that may relapse
- Pleural effusion, pericardial effusion, or intraperitoneal effusion accompanied with clinical symptoms, clinically poorly controlled, or requiring repeated drainage
- Allergies to any component of ALK201 or other monoclonal antibodies
- Primary central nervous system malignancies, or active metastases to central nervous system and/or metastases to meninges
- Combined with ≥ Grade 2 stomatitis and/or nose bleeding at screening
- Vaccinated with live vaccines within 4 weeks prior to the first dose
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: Dose-escalation Phase, Part B: Dose-expansion Phase
A dose-escalation study to determine the MTD and the subsequent doses for dose expansion study (Part B). A dose-expansion study which will enroll the select indications. |
Administered intravenously, once every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the safety and tolerability of ALK201 in adult participants with advanced solid tumors; To determine the maximum tolerated dose (MTD); To determine the recommended dose(s) of ALK201 for subsequent clinical studies.
Time Frame: Approximately 36 months
|
Dose-limiting toxicity (DLT); The incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) according to CTCAE v5.0.
|
Approximately 36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the pharmacokinetics (PK) of ALK201.
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: area under the concentration-time curve from time zero to the last measurement (AUC0-last)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: area under the concentration-time curve from time zero to infinity (AUC0-inf)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: Maximum serum Concentration (Cmax)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: Time to Maximum Concentration(Tmax)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: trough Concentration(Ctrough)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: Clearance(CL)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: apparent Distribution Volume(Vd)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: steady-state apparent distribution volume (Vss)
|
Approximately 36 months
|
|
To evaluate the pharmacokinetics (PK) of ALK201
Time Frame: Approximately 36 months
|
PK parameters after single and multiple doses: terminal half-life (t1/2)
|
Approximately 36 months
|
|
To evaluate the immunogenicity of ALK201.
Time Frame: Approximately 36 months
|
The generation of anti-drug antibodies (ADAs).
|
Approximately 36 months
|
|
To evaluate the preliminary antitumor activity of ALK201
Time Frame: Approximately 36 months
|
Objective Response Rate (ORR)
|
Approximately 36 months
|
|
To evaluate the preliminary antitumor activity of ALK201
Time Frame: Approximately 36 months
|
Duration of Response (DOR)
|
Approximately 36 months
|
|
To evaluate the preliminary antitumor activity of ALK201
Time Frame: Approximately 36 months
|
Disease Control Rate (DCR)
|
Approximately 36 months
|
|
To evaluate the preliminary antitumor activity of ALK201
Time Frame: Approximately 36 months
|
Progression-Free Survival (PFS)
|
Approximately 36 months
|
|
To evaluate the preliminary antitumor activity of ALK201
Time Frame: Approximately 36 months
|
Overall Survival (OS)
|
Approximately 36 months
|
|
To evaluate the biomarkers.
Time Frame: Approximately 36 months
|
Descriptive analysis will be made to describe the correlation between clinical outcomes and FGFR2 genetic alterations.
|
Approximately 36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ALK201-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.